
Investing.com -- Walgreens Boots Alliance (NASDAQ:WBA) has posted first-quarter income that topped analysts expectations thanks to strong demand at its pharmacy business and international segments.
The Illinois-based company, which has been attempting to slash costs to offset weaker discretionary spending by customers as well as lower contributions from COVID-19 vaccines and testing, also lowered its quarterly dividend by 48% to $0.25.
In a statement, Chief Executive Officer Tim Wentworth called the decision "difficult," but said it was necessary to "strengthen our long-term balance sheet and cash position."
Wentworth, who was tapped to take the helm of the drugstore chain operator in October, added that the move will also free up capital to invest in Walgreens' pharmacy and healthcare businesses.
"We are evaluating all strategic options to drive sustainable long-term shareholder value, focusing on swift actions to right-size costs and increase cash flow, with a balanced approach to capital allocation priorities," Wentworth said.
Adjusted earnings per share decreased by 43.1% to $0.66 in the three months ended on Nov. 30, yet still beat Bloomberg consensus estimates of $0.62. Sales of $36.71 billion were also above projections despite a "challenging" retail market environment and headwinds from a higher tax rate.
For its 2024 fiscal year, Walgreens maintained its outlook for adjusted per-share profit of $3.20 to $3.50. Analysts had called for guidance of $3.32.
Shares in Walgreens rose in premarket trading in New York on Thursday.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.